CU24316B1 - Nuevos derivados fosfatos de 1,2,3,4-tetraisoquinolina amida fenilo, métodos de preparación de los mismos y composiciones farmacéuticas que los contienen - Google Patents

Nuevos derivados fosfatos de 1,2,3,4-tetraisoquinolina amida fenilo, métodos de preparación de los mismos y composiciones farmacéuticas que los contienen

Info

Publication number: CU24316B1
Authority: CU; Cuba
Prior art keywords: formula; compounds; preparation; tetraisoquinolina; phyphate
Prior art date: 2013-07-23

Application number

CUP2014000095A

Other languages

English (en)

Spanish (es)

Other versions

CU20140095A7 (es

Inventor

I Jen Chen

James Edward Paul Davidson

Nanteuil Guillaume De

Olivier Geneste

Anne Françoise Guillouzic

Jean Michel Henlin

Diguarher Thierry Le

Tiran Arnaud Le

James Brooke Murray

Jerome Benoît Starck

Original Assignee

Servier Lab

Vernalis R&D Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-07-23

Filing date

2014-07-23

Publication date

2018-02-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50288170&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU24316(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-07-23 Application filed by Servier Lab, Vernalis R&D Ltd filed Critical Servier Lab

2016-02-29 Publication of CU20140095A7 publication Critical patent/CU20140095A7/es

2018-02-08 Publication of CU24316B1 publication Critical patent/CU24316B1/xx

Links

238000002360 preparation method Methods 0.000 title abstract 2
241000670727 Amida Species 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 7
206010028980 Neoplasm Diseases 0.000 abstract 1
229910019142 PO4 Inorganic materials 0.000 abstract 1
108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 abstract 1
102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 abstract 1
206010041067 Small cell lung cancer Diseases 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
150000001412 amines Chemical class 0.000 abstract 1
230000006909 anti-apoptosis Effects 0.000 abstract 1
150000007942 carboxylates Chemical class 0.000 abstract 1
150000001735 carboxylic acids Chemical class 0.000 abstract 1
238000002512 chemotherapy Methods 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
125000002485 formyl group Chemical class [H]C(*)=O 0.000 abstract 1
230000003211 malignant effect Effects 0.000 abstract 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
239000010452 phosphate Substances 0.000 abstract 1
150000003013 phosphoric acid derivatives Chemical class 0.000 abstract 1
208000000587 small cell lung carcinoma Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pathology (AREA)
Radiology & Medical Imaging (AREA)
Oncology (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

CUP2014000095A 2013-07-23 2014-07-23 Nuevos derivados fosfatos de 1,2,3,4-tetraisoquinolina amida fenilo, métodos de preparación de los mismos y composiciones farmacéuticas que los contienen CU24316B1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR1357259A FR3008979B1 (fr)	2013-07-23	2013-07-23	Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (2)

Publication Number	Publication Date
CU20140095A7 CU20140095A7 (es)	2016-02-29
CU24316B1 true CU24316B1 (es)	2018-02-08

Family

ID=50288170

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CUP2014000095A CU24316B1 (es)	2013-07-23	2014-07-23	Nuevos derivados fosfatos de 1,2,3,4-tetraisoquinolina amida fenilo, métodos de preparación de los mismos y composiciones farmacéuticas que los contienen

Country Status (48)

Country	Link
US (3)	US9115159B2 (de)
EP (1)	EP2829545B1 (de)
JP (1)	JP5894638B2 (de)
KR (2)	KR101713103B1 (de)
CN (1)	CN104341451B (de)
AP (1)	AP2014007773A0 (de)
AR (1)	AR097008A1 (de)
AU (1)	AU2014203808B2 (de)
BR (1)	BR102014017997B1 (de)
CA (1)	CA2856886C (de)
CL (1)	CL2014001865A1 (de)
CR (1)	CR20140336A (de)
CU (1)	CU24316B1 (de)
CY (1)	CY1117834T1 (de)
DK (1)	DK2829545T3 (de)
DO (1)	DOP2014000163A (de)
EA (1)	EA027444B1 (de)
EC (1)	ECSP14008757A (de)
ES (1)	ES2593417T3 (de)
FR (1)	FR3008979B1 (de)
GE (1)	GEP201706704B (de)
HK (1)	HK1204623A1 (de)
HR (1)	HRP20161202T8 (de)
HU (1)	HUE029616T2 (de)
IL (1)	IL233580B (de)
JO (1)	JO3160B1 (de)
MA (1)	MA37213B1 (de)
MD (1)	MD4551C1 (de)
ME (1)	ME02641B (de)
MX (1)	MX351467B (de)
MY (1)	MY173258A (de)
NI (1)	NI201400080A (de)
PE (1)	PE20150218A1 (de)
PH (1)	PH12014000194A1 (de)
PL (1)	PL2829545T3 (de)
PT (1)	PT2829545T (de)
RS (1)	RS55098B1 (de)
RU (1)	RU2617682C2 (de)
SA (1)	SA114350669B1 (de)
SG (1)	SG10201403939WA (de)
SI (1)	SI2829545T1 (de)
SV (1)	SV2014004771A (de)
TN (1)	TN2014000301A1 (de)
TW (1)	TWI527824B (de)
UA (1)	UA119738C2 (de)
UY (1)	UY35661A (de)
WO (1)	WO2015011399A1 (de)
ZA (1)	ZA201405418B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8461179B1 (en)	2012-06-07	2013-06-11	Deciphera Pharmaceuticals, Llc	Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
FR3008977A1 (fr) *	2013-07-23	2015-01-30	Servier Lab	Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008976A1 (fr) *	2013-07-23	2015-01-30	Servier Lab	"nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
UY37316A (es) *	2016-07-07	2018-01-31	Servier Lab	Dispersión sólida farmacéutica de un inhibidor de bcl-2, composiciones farmacéuticas de ésta, y usos para el tratamiento de cáncer
SG10202013206TA (en) *	2016-07-22	2021-02-25	Servier Lab	Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof
UY37342A (es) *	2016-07-22	2018-01-31	Servier Lab	Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos
WO2018158225A1 (en)	2017-02-28	2018-09-07	Les Laboratoires Servier	Combination of a bcl-2 inhibitor and a mdm2 inhibitor, uses and pharmaceutical compositions thereof
EA039621B1 (ru) *	2017-06-09	2022-02-17	Ле Лаборатуар Сервье	Комбинация bcl-2 ингибитора и mcl-1 ингибитора, их применения и фармацевтические композиции
WO2019008126A1 (en) *	2017-07-06	2019-01-10	Les Laboratoires Servier	NOVEL CRYSTALLINE FORM OF BCL-2 INHIBITOR, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
FR3072679B1 (fr) *	2017-10-25	2020-10-30	Servier Lab	Nouveaux derives macrocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
SG11202007198WA (en)	2018-01-31	2020-08-28	Deciphera Pharmaceuticals Llc	Combination therapy for the treatment of gastrointestinal stromal tumors
EA202091763A1 (ru)	2018-01-31	2020-12-14	ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи	Комбинированная терапия для лечения мастоцитоза
EP3938363A1 (de)	2019-03-11	2022-01-19	Teva Pharmaceuticals International GmbH	Festkörperformen von ripretinib
JP7818502B2 (ja)	2019-08-12	2026-02-20	デシフェラ・ファーマシューティカルズ，エルエルシー	胃腸間質腫瘍を治療するためのリプレチニブ
WO2021030405A1 (en)	2019-08-12	2021-02-18	Deciphera Pharmaceuticals, Llc	Ripretinib for treating gastrointestinal stromal tumors
CN110606860B (zh)	2019-09-29	2021-12-10	上海勋和医药科技有限公司	一种吡啶磺酰胺磷酸酯类化合物、其制备方法及其用途
AU2020417282B2 (en)	2019-12-30	2023-08-31	Deciphera Pharmaceuticals, Llc	Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
SI4084778T1 (sl)	2019-12-30	2024-01-31	Deciphera Pharmaceuticals, Llc	Formulacije inhibitorja amorfne kinaze in načini njihove uporabe
BR112023017344A2 (pt) *	2021-03-12	2023-09-26	Eil Therapeutics Inc	Compostos que têm tetra-hidroindolizina-1-carboxamida como inibidores de bcl-2
US20250002491A1 (en)	2021-10-04	2025-01-02	Forx Therapeutics Ag	N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
US20250387504A1 (en)	2022-05-20	2025-12-25	Novartis Ag	Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
US11779572B1 (en)	2022-09-02	2023-10-10	Deciphera Pharmaceuticals, Llc	Methods of treating gastrointestinal stromal tumors
WO2025111431A1 (en)	2023-11-22	2025-05-30	Les Laboratoires Servier	Anti-cd7 antibody-drug conjugates and methods of use thereof
TW202540185A (zh)	2023-11-22	2025-10-16	法商施維雅藥廠	抗cd74抗體藥物結合物及其使用方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4901102B2 (ja) *	2002-05-03	2012-03-21	エクセリクシス，インク．	プロテインキナーゼモジュレーターおよびその使用方法
WO2004004727A1 (en) *	2002-07-03	2004-01-15	Axys Pharmaceuticals, Inc.	3,4-dihydroisoquinolin-1-one derivatives as inducers of apoptosis
GB0224557D0 (en) *	2002-10-22	2002-11-27	Glaxo Group Ltd	Novel compounds
BRPI0620151A2 (pt)	2005-12-22	2010-06-29	Wyeth Corp	composto; composição farmacêutica; método de tratar ou inibir o crescimento de células tumorais cancerosas em um mamìfero que deste necessita; método; e processo
US7902218B2 (en)	2006-12-12	2011-03-08	Bristol-Myers Squibb Company	Substituted tetrahydroisoquinolines as β-secretase inhibitors
CA2682356C (en) *	2007-04-16	2016-06-14	Abbott Laboratories	7-substituted indole mcl-1 inhibitors
US8263607B2 (en)	2007-05-22	2012-09-11	Astellas Pharma Inc.	1-substituted tetrahydroisoquinoline compound
EP2252617A1 (de) *	2008-02-13	2010-11-24	CGI Pharmaceuticals, Inc.	6-arylimidazo[1,2-a]pyrazinderivate, herstellungsverfahren und verfahren zu deren anwendung
CA2747170C (en) *	2008-12-19	2017-07-18	Abbott Laboratories	Tetrahydroisoquinoline derivatives and their uses to treat cancers and autoimmune disorders
TWI520960B (zh) *	2010-05-26	2016-02-11	艾伯維有限公司	用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
US20120301080A1 (en)	2011-05-23	2012-11-29	Senko Advanced Components, Inc.	True one piece housing fiber optic adapter
WO2013096055A1 (en)	2011-12-23	2013-06-27	Novartis Ag	Compounds for inhibiting the interaction of bcl2 with binding partners
BR112014015322A8 (pt)	2011-12-23	2017-06-13	Novartis Ag	compostos e composições para inibir a interação de bcl2 com parceiros de ligação
CA2859873A1 (en)	2011-12-23	2013-06-27	Novartis Ag	Compounds for inhibiting the interaction of bcl2 with binding partners
CN104125955A (zh)	2011-12-23	2014-10-29	诺华股份有限公司	用于抑制bcl2与结合配偶体相互作用的化合物
MX2014007731A (es)	2011-12-23	2015-01-12	Novartis Ag	Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace.
CN103177906A (zh)	2011-12-26	2013-06-26	西门子公司	用于中压开关设备的断路器
ITPR20110103A1 (it)	2011-12-27	2013-06-28	G E A F S R L	Metodo e apparato per la sterilizzazione di una soluzione liquida mediante radio frequenza
US9114953B2 (en)	2011-12-29	2015-08-25	Inventio Ag	Emergency operation of elevators based on an indicated emergency condition
FR2986002B1 (fr) *	2012-01-24	2014-02-21	Servier Lab	Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
IN2012DE00210A (de)	2012-01-24	2015-06-19	Danfoss As

2013
- 2013-07-23 FR FR1357259A patent/FR3008979B1/fr active Active
2014
- 2014-07-08 PH PH12014000194A patent/PH12014000194A1/en unknown
- 2014-07-09 AP AP2014007773A patent/AP2014007773A0/xx unknown
- 2014-07-09 SG SG10201403939WA patent/SG10201403939WA/en unknown
- 2014-07-09 JO JOP/2014/0222A patent/JO3160B1/ar active
- 2014-07-10 MY MYPI2014701887A patent/MY173258A/en unknown
- 2014-07-10 IL IL233580A patent/IL233580B/en active IP Right Grant
- 2014-07-10 PE PE2014001093A patent/PE20150218A1/es active IP Right Grant
- 2014-07-10 EC ECIEPI20148757A patent/ECSP14008757A/es unknown
- 2014-07-11 AU AU2014203808A patent/AU2014203808B2/en active Active
- 2014-07-11 UY UY35661A patent/UY35661A/es unknown
- 2014-07-11 TN TNP2014000301A patent/TN2014000301A1/fr unknown
- 2014-07-11 CR CR20140336A patent/CR20140336A/es unknown
- 2014-07-14 CA CA2856886A patent/CA2856886C/fr active Active
- 2014-07-15 MD MDA20140073A patent/MD4551C1/ro not_active IP Right Cessation
- 2014-07-15 CL CL2014001865A patent/CL2014001865A1/es unknown
- 2014-07-15 MA MA37213A patent/MA37213B1/fr unknown
- 2014-07-15 DO DO2014000163A patent/DOP2014000163A/es unknown
- 2014-07-17 UA UAA201408109A patent/UA119738C2/uk unknown
- 2014-07-17 SV SV2014004771A patent/SV2014004771A/es unknown
- 2014-07-21 GE GEAP201413528A patent/GEP201706704B/en unknown
- 2014-07-22 RS RS20160693A patent/RS55098B1/sr unknown
- 2014-07-22 ES ES14178030.4T patent/ES2593417T3/es active Active
- 2014-07-22 RU RU2014130129A patent/RU2617682C2/ru active
- 2014-07-22 BR BR102014017997A patent/BR102014017997B1/pt active IP Right Grant
- 2014-07-22 ZA ZA2014/05418A patent/ZA201405418B/en unknown
- 2014-07-22 SA SA114350669A patent/SA114350669B1/ar unknown
- 2014-07-22 MX MX2014008866A patent/MX351467B/es active IP Right Grant
- 2014-07-22 DK DK14178030.4T patent/DK2829545T3/en active
- 2014-07-22 PT PT141780304T patent/PT2829545T/pt unknown
- 2014-07-22 SI SI201430059A patent/SI2829545T1/sl unknown
- 2014-07-22 NI NI201400080A patent/NI201400080A/es unknown
- 2014-07-22 EP EP14178030.4A patent/EP2829545B1/de active Active
- 2014-07-22 TW TW103125160A patent/TWI527824B/zh not_active IP Right Cessation
- 2014-07-22 EA EA201400754A patent/EA027444B1/ru unknown
- 2014-07-22 WO PCT/FR2014/051887 patent/WO2015011399A1/fr not_active Ceased
- 2014-07-22 US US14/337,577 patent/US9115159B2/en active Active
- 2014-07-22 PL PL14178030.4T patent/PL2829545T3/pl unknown
- 2014-07-22 HU HUE14178030A patent/HUE029616T2/en unknown
- 2014-07-22 AR ARP140102712A patent/AR097008A1/es unknown
- 2014-07-22 ME MEP-2016-208A patent/ME02641B/de unknown
- 2014-07-22 JP JP2014148946A patent/JP5894638B2/ja active Active
- 2014-07-23 KR KR1020140093393A patent/KR101713103B1/ko active Active
- 2014-07-23 CU CUP2014000095A patent/CU24316B1/xx unknown
- 2014-07-23 CN CN201410354089.1A patent/CN104341451B/zh active Active
2015
- 2015-06-01 HK HK15105213.3A patent/HK1204623A1/xx unknown
- 2015-07-16 US US14/800,871 patent/US9597341B2/en active Active
2016
- 2016-07-18 CY CY20161100696T patent/CY1117834T1/el unknown
- 2016-09-20 HR HRP20161202TT patent/HRP20161202T8/hr unknown
- 2016-12-23 KR KR1020160177980A patent/KR20170001694A/ko not_active Withdrawn
2017
- 2017-02-06 US US15/425,119 patent/US20170143746A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AR097008A1 (es)	2016-02-10
FR3008979A1 (fr)	2015-01-30
US20150313923A1 (en)	2015-11-05
EA027444B1 (ru)	2017-07-31
JP2015028017A (ja)	2015-02-12
CN104341451A (zh)	2015-02-11
ME02641B (de)	2017-06-20
SA114350669B1 (ar)	2016-04-11
JO3160B1 (ar)	2017-09-20
IL233580B (en)	2020-03-31
EP2829545A1 (de)	2015-01-28
IL233580A0 (en)	2014-11-02
AU2014203808B2 (en)	2018-09-20
CA2856886C (fr)	2016-08-02
CN104341451B (zh)	2018-04-03
TN2014000301A1 (fr)	2015-12-21
CR20140336A (es)	2015-10-07
HK1204623A1 (en)	2015-11-27
FR3008979B1 (fr)	2015-07-24
CA2856886A1 (fr)	2015-01-23
TWI527824B (zh)	2016-04-01
BR102014017997B1 (pt)	2020-05-19
UA119738C2 (uk)	2019-08-12
NZ627178A (en)	2016-01-29
AP2014007773A0 (en)	2014-07-31
US20170143746A1 (en)	2017-05-25
PE20150218A1 (es)	2015-02-14
EA201400754A3 (ru)	2015-03-31
MD4551C1 (ro)	2018-09-30
ZA201405418B (en)	2020-02-26
US20150031648A1 (en)	2015-01-29
EP2829545B1 (de)	2016-06-22
US9597341B2 (en)	2017-03-21
SV2014004771A (es)	2015-01-28
CL2014001865A1 (es)	2015-06-26
MX351467B (es)	2017-10-17
BR102014017997A2 (pt)	2015-11-17
PT2829545T (pt)	2016-07-13
KR101713103B1 (ko)	2017-03-07
RS55098B1 (sr)	2016-12-30
ES2593417T3 (es)	2016-12-09
MX2014008866A (es)	2015-07-21
HUE029616T2 (en)	2017-03-28
RU2617682C2 (ru)	2017-04-26
ECSP14008757A (es)	2016-01-29
MD4551B1 (ro)	2018-02-28
HK1201536A1 (zh)	2015-09-04
SI2829545T1 (sl)	2016-10-28
MA37213A1 (fr)	2016-06-30
PH12014000194B1 (en)	2015-06-29
CY1117834T1 (el)	2017-05-17
US9115159B2 (en)	2015-08-25
KR20170001694A (ko)	2017-01-04
GEP201706704B (en)	2017-07-25
TW201504254A (zh)	2015-02-01
DK2829545T3 (en)	2016-09-19
HRP20161202T1 (hr)	2016-11-04
EA201400754A2 (ru)	2014-12-30
PH12014000194A1 (en)	2015-06-29
RU2014130129A (ru)	2016-02-10
MD20140073A2 (en)	2015-01-31
NI201400080A (es)	2014-10-24
KR20150011785A (ko)	2015-02-02
HRP20161202T8 (hr)	2016-12-30
JP5894638B2 (ja)	2016-03-30
CU20140095A7 (es)	2016-02-29
PL2829545T3 (pl)	2016-12-30
SG10201403939WA (en)	2015-02-27
MA37213B1 (fr)	2017-03-31
DOP2014000163A (es)	2015-01-15
AU2014203808A1 (en)	2015-02-12
MY173258A (en)	2020-01-09
WO2015011399A1 (fr)	2015-01-29
UY35661A (es)	2015-02-27

Publication	Publication Date	Title
CU24316B1 (es)	2018-02-08	Nuevos derivados fosfatos de 1,2,3,4-tetraisoquinolina amida fenilo, métodos de preparación de los mismos y composiciones farmacéuticas que los contienen
CY1121744T1 (el)	2020-07-31	Παραγωγα c4-μονομεθυλο-τριτερπενοειδους και μεθοδοι χρησης αυτων
CY1121776T1 (el)	2020-07-31	C17-αλκανοδιυλιο και παραγωγα αλκενοδιυλιου του ολεανολικου οξεος και μεθοδοι χρησης αυτων
MX377552B (es)	2025-03-10	Proceso para preparar un compuesto antiviral de formula i.
AR097158A1 (es)	2016-02-24	Polimorfo de inhibidores de tirosina quinasa de bazo (syk)
EA201592144A1 (ru)	2016-07-29	Производное фенола, способ его получения и его применение в медицине
EA201690072A1 (ru)	2016-06-30	Состав, содержащий гиполипидемическое средство
JO3221B1 (ar)	2018-03-08	مركبات حمض داي ميثيل - بنزويك مفيدة لعلاج الحالات الالتهابية
AR088551A1 (es)	2014-06-18	Conjugados de hidromorfona con acido benzoico, derivados de acido benzoico y acido heteroarilcarboxilico; profarmacos, metodos de preparacion y uso de los mismos
EA201291217A1 (ru)	2013-09-30	ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ
PH12015501752A1 (en)	2015-11-09	Substituted bisphenyl butanoic phosphonic acid derivatives as nep inhibitors
AR105494A1 (es)	2017-10-11	Método para preparar derivados de ácido 3-(2-anilino-1-ciclohexil-1h-bencimidazol-5-il)propanoico sustituido
UY32004A (es)	2010-02-26	Derivados de carbamatos de alquiltiazoles, su preparación y su aplicación en terapéutica
BR112014004523A2 (pt)	2017-03-28	composto e composição aromatizante
UY32295A (es)	2010-06-30	Dihidroetorfina
WO2020132471A8 (en)	2020-08-06	Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof
AR041937A1 (es)	2005-06-01	Proceso para la preparacion de derivados de carboestirilo
AR084209A1 (es)	2013-05-02	Metodo para la sintesis de derivados de aminociclohexanona sustituidos
AR081034A1 (es)	2012-05-30	Derivados de n-heteroaril tetrahidro-isoquinolina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades del sistema nervioso central
MX2020009462A (es)	2021-08-31	Procesos para la preparación de compuestos de pirimidinilciclopentano.
ES2524086T3 (es)	2014-12-04	Nuevo método para la preparación de ezetimiba
EA201591487A1 (ru)	2015-12-30	Производные замещенной бисфенилбутановой кислоты в качестве ингибиторов nep с улучшенной in vivo эффективностью
AR082593A1 (es)	2012-12-19	Proceso para la preparacion de pirazoles
CY1116477T1 (el)	2017-03-15	Μεθοδος εnzυμatiκης συνθεσης toy (7s)-3,4-διμεθοξυδικυκλο[4.2.0] οκτα-1,3,5-τριενo-7-καρβοξυλικου οξεος ή εστερων αυτου και εφαρμογη στην συνθεση της ιβαμπραδινης και των αλατων αυτης
CY1120482T1 (el)	2019-07-10	Μεθοδος συνθεσης 3,4-διμεθοξυδικυκλο[4.2.0]οκτα-1,3,5-τριενο-7-καρβονιτριλιου και εφαρμογη στη συνθεση της ιβαμπραδινης και των αλατων προσθηκης αυτης με ενα φαρμακευτικως αποδεκτο οξy